- Home
- PSNL vs KURA Comparison
PSNL vs KURA Comparison
Compare PSNL & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- KURA
- Stock Information
- Founded
- PSNL 2011
- KURA 2014
- Country
- PSNL United States
- KURA United States
- Employees
- PSNL N/A
- KURA N/A
- Industry
- PSNL Medical Specialities
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSNL Health Care
- KURA Health Care
- Exchange
- PSNL Nasdaq
- KURA Nasdaq
- Market Cap
- PSNL 854.8M
- KURA 884.1M
- IPO Year
- PSNL 2019
- KURA N/A
- Fundamental
- Price
- PSNL $7.79
- KURA $11.24
- Analyst Decision
- PSNL Strong Buy
- KURA Strong Buy
- Analyst Count
- PSNL 7
- KURA 13
- Target Price
- PSNL $10.43
- KURA $25.40
- AVG Volume (30 Days)
- PSNL 1.5M
- KURA 2.4M
- Earning Date
- PSNL 11-04-2025
- KURA 11-04-2025
- Dividend Yield
- PSNL N/A
- KURA N/A
- EPS Growth
- PSNL N/A
- KURA N/A
- EPS
- PSNL N/A
- KURA N/A
- Revenue
- PSNL $69,103,000.00
- KURA $104,029,000.00
- Revenue This Year
- PSNL N/A
- KURA $68.63
- Revenue Next Year
- PSNL $29.83
- KURA $141.59
- P/E Ratio
- PSNL N/A
- KURA N/A
- Revenue Growth
- PSNL N/A
- KURA N/A
- 52 Week Low
- PSNL $2.83
- KURA $5.41
- 52 Week High
- PSNL $10.95
- KURA $16.68
- Technical
- Relative Strength Index (RSI)
- PSNL 46.21
- KURA 62.91
- Support Level
- PSNL $6.63
- KURA $9.51
- Resistance Level
- PSNL $9.89
- KURA $12.49
- Average True Range (ATR)
- PSNL 0.80
- KURA 0.95
- MACD
- PSNL -0.21
- KURA 0.06
- Stochastic Oscillator
- PSNL 32.79
- KURA 65.63
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.